{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:38:28Z","timestamp":1770971908862,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Age and sex are known to influence outcomes in neuroendocrine neoplasms (NENs), yet their molecular determinants remain poorly defined. We queried a real-world dataset of gastrointestinal (GI) tract and pancreatic (P) NENs and characterized their clinical, molecular, and immune profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One thousand nine hundred thirty-five cases (GI: n\u2009=\u20091431, P: n\u2009=\u2009504) of NENs were analyzed using Next Generation or Whole Exome Sequencing of DNA, and 1211\/1935 cases (GI: n\u2009=\u2009917, P: n\u2009=\u2009294) underwent Whole Transcriptome Sequencing. We compared the molecular and immune profile with respect to age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Older age at diagnosis was associated with worse survival in both GI- and P-NENs. In patients with GI-NENs, there was decreased survival in males compared to females. In GI-NENs, TP53, RB1, FAT1, and KMT2D mutations, as well as immune checkpoint gene (ICG) expressions of LAG3, CD80, and HAVCR2 and M1 macrophages increased with increasing age while APC mutations and M2 macrophages decreased with increasing age. In P-NENs, TP53, RB1, KRAS, and SMAD4 mutations and CD4+ T cells increased with increasing age while MUTYH and NTHL1 mutations and M2 macrophages decreased with increasing age. In GI-NENs, TP53, FBXW7, and TERT (promoter) mutations and genomic loss of heterozygosity (gLOH) were increased in males. In P-NENs, PIK3CA mutations and dMMR\/MSI-H were increased in females.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study queries one of the largest datasets of GI- and P-NENs to date and highlights distinct age- and sex-specific molecular and immune profiles. Given the exploratory nature of these analyses and borderline significance, these results remain hypothesis-generating, providing an initial framework for future validation studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf440","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T12:40:05Z","timestamp":1767271205000},"source":"Crossref","is-referenced-by-count":0,"title":["Age- and sex-based differences in the genomic profiles of patients with gastrointestinal and pancreatic neuroendocrine neoplasms"],"prefix":"10.1093","volume":"31","author":[{"given":"Shuning","family":"Li","sequence":"first","affiliation":[{"name":"Fox Chase Cancer Center, Temple University Health System , Philadelphia, PA 19111,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Liu","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Temple University Health System , Philadelphia, PA 19111,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Farrell","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heloisa","family":"Soares","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah , Salt Lake City, UT 84112,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Swensen","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-2513","authenticated-orcid":false,"given":"Matthew","family":"Oberley","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G","family":"Evans","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Kunz","sequence":"additional","affiliation":[{"name":"Smilow Cancer Hospital\/Yale Cancer Center, Yale University , North Haven, CT 06510,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-4759","authenticated-orcid":false,"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Temple University Health System , Philadelphia, PA 19111,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026021302362775700_oyaf440-B1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"2026021302362775700_oyaf440-B2","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1158\/1078-0432","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026021302362775700_oyaf440-B3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/bjc.2016.229","article-title":"Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study","volume":"115","author":"Vijayvergia","year":"2016","journal-title":"Br J Cancer"},{"key":"2026021302362775700_oyaf440-B4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Francis","year":"2013","journal-title":"Nat Genet"},{"key":"2026021302362775700_oyaf440-B5","doi-asserted-by":"publisher","first-page":"22464","DOI":"10.1038\/s41598-021-01850-x","article-title":"An age stratified analysis of the biomarkers in patients with colorectal cancer","volume":"11","author":"Yao","year":"2021","journal-title":"Sci Rep"},{"key":"2026021302362775700_oyaf440-B6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","article-title":"Comprehensive characterization of molecular differences in cancer between male and female patients","volume":"29","author":"Yuan","year":"2016","journal-title":"Cancer Cell"},{"key":"2026021302362775700_oyaf440-B7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/MPA.0000000000001821","article-title":"Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study","volume":"50","author":"Abdel-Rahman","year":"2021","journal-title":"Pancreas"},{"key":"2026021302362775700_oyaf440-B8","doi-asserted-by":"publisher","first-page":"1073274820986827","DOI":"10.1177\/1073274820986827","article-title":"Clinical characteristics and prognostic factors of early-onset pancreatic neuroendocrine tumors","volume":"28","author":"Shi","year":"2021","journal-title":"Cancer Control"},{"key":"2026021302362775700_oyaf440-B9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026021302362775700_oyaf440-B10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"},{"key":"2026021302362775700_oyaf440-B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2026021302362775700_oyaf440-B12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1159\/000503722","article-title":"Gastroenteropancreatic high-grade neuroendocrine neoplasms: histology and molecular analysis, two sides of the same coin","volume":"110","author":"Busico","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026021302362775700_oyaf440-B13","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026021302362775700_oyaf440-B14","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3390\/cancers12092501","article-title":"Distinct clinical characteristics in Young-Onset pancreatic neuroendocrine tumor","volume":"12","author":"Goksu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026021302362775700_oyaf440-B15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.2008.00607.x","article-title":"The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance","volume":"222","author":"Allavena","year":"2008","journal-title":"Immunol Rev"},{"key":"2026021302362775700_oyaf440-B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/endoabs.98.P11","article-title":"Sex differences during hospital stay among patients with neuroendocrine neoplasms","volume":"98","author":"Tan","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"2026021302362775700_oyaf440-B17","doi-asserted-by":"publisher","first-page":"CD015169","DOI":"10.1002\/14651858.CD015169","article-title":"First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis","volume":"10","author":"Miyamoto","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021302362775700_oyaf440-B18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000486096","article-title":"The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines","volume":"106","author":"Zandee","year":"2018","journal-title":"Neuroendocrinology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf440\/66285460\/oyaf440.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf440\/66285460\/oyaf440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf440\/66285460\/oyaf440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:34Z","timestamp":1770968194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf440\/8415880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf440","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,6]]},"article-number":"oyaf440"}}